Gilead Sciences Announces Phase 3 ELUCID Trial Results for Seladelpar in NASH

Gilead Sciences today announced results from the Phase 3 ELUCID trial evaluating seladelpar in patients with nonalcoholic steatohepatitis (NASH). The trial met its primary endpoint, demonstrating a statistically significant improvement in NASH resolution without worsening of fibrosis compared to placebo. The NASH resolution rate was 26.5% for seladelpar versus 12.8% for placebo at 52 weeks. Seladelpar is a selective PPARδ agonist that targets the underlying metabolic and inflammatory pathways in NASH. These results support regulatory submissions for seladelpar in NASH, a condition with very limited approved treatment options.